| abstract |
The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1- methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper- proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per day, particularly in an amount of 60 to 160 mg per day. The present invention also relates to a pharmaceutical composition comprising 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5- yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient. The present invention also relates to a process for manufacturing said pharmaceutical composition. |